1. Introduction {#s0005}
===============

Phenylketonuria (PKU) is a recessive hereditary disorder characterized by deficient or absent phenylalanine hydroxylase (PAH). Consequently, catalysis of phenylalanine (Phe) is disrupted, and concentrations of blood Phe are elevated [@bb0180]. If untreated, PKU may lead to profound neurologic problems and intellectual disability [@bb0155], [@bb0160].

In recent decades, the most severe of these neural and cognitive consequences have been mitigated by newborn screening programs that identify infants with PKU and implement dietary treatment to limit Phe intake. Nevertheless, individuals with early- and continuously-treated PKU exhibit brain abnormalities [@bb0010], [@bb0015], [@bb0040], [@bb0055], score slightly lower than expected on tests of intelligence [@bb0175], and are at increased risk for executive (for review, see [@bb0050]), psychosocial, and psychiatric difficulties [@bb0045], [@bb0100], [@bb0215].

Dietary restriction of Phe-containing foods remains the most commonly prescribed treatment for PKU, but emerging treatments hold promise for the future [@bb0200], [@bb0225]. One promising pharmaceutical treatment is a synthetic form of tetrahydrobiopterin (BH~4~), sapropterin dihydrochloride. BH~4~ is a cofactor for PAH, facilitating the conversion of Phe into tyrosine and thereby reducing blood Phe in a subset of individuals with PKU who have residual PAH activity [@bb0150].

Although there is some debate regarding the degree to which blood Phe must be reduced to consider an individual a responder to BH~4~ [@bb0190], [@bb0230], responsiveness is often defined as a reduction in Phe ≥ 30% compared to a pretreatment baseline [@bb0030]. In the present study, BH~4~ responders exhibited average reductions in Phe ≥ 30% over the course of 4 weeks of treatment. Previous studies using a similar reduction criterion found that 38--54% of individuals with PKU responded to BH~4~ within 8 h of administration [@bb0090], [@bb0095], 46--52% responded within 24 h of administration [@bb0090], [@bb0095], and 50% responded within 48 h of administration [@bb0095].

Factors distinguishing BH~4~ responders from non-responders are not well understood. Although evidence suggests that individuals with mild PKU respond better than those with classic PKU [@bb0130], a subset of individuals with classic PKU nonetheless respond to the drug [@bb0105], [@bb0145]. In addition, biochemical [@bb0110], [@bb0125] and genetic [@bb0110], [@bb0130], [@bb0170] variables may differ between responders and non-responders. For example, in the biochemical domain, Humphrey et al. [@bb0125] found that non-responders typically have greater variability in blood Phe and a higher Phe to tyrosine ratio than responders. In the genetic domain, Karačić et al. [@bb0130] linked BH~4~ responsiveness to mutations on the 12q22-24 chromosome of the gene encoding PAH.

In contrast with the proliferation of research on biochemical and genetic differences between BH~4~ responders and non-responders, cognitive and neural differences remain largely unexplored. The present study aimed to address this gap in knowledge. To do so, we examined data related to indices of Phe control, microstructural white matter integrity, and intelligence that were collected prior to BH~4~ administration in individuals who were subsequently identified as BH~4~ responders and non-responders. To provide a normative context for results, comparisons were also made with a healthy non-PKU control group.

2. Material and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

Individuals with classic PKU (*n* = 29; 18 males, 11 females) were recruited through metabolic clinics at St. Louis Children\'s Hospital (*n* = 11), University of Missouri (*n* = 7), University of Florida (*n* = 4), St. Louis University (*n* = 3), Washington University (*n* = 2), New York Medical College (*n* = 1), and University of Nebraska (*n* = 1), with all cognitive assessment and neuroimaging procedures conducted at either Washington University (*n* = 19) or University of Missouri (*n* = 10). All individuals were diagnosed in early infancy and thereafter placed on continuous dietary treatment to limit Phe intake. No individual had a history of major medical, psychiatric, or learning disorder unrelated to PKU.

Baseline cognitive, neuroimaging, and blood Phe data were obtained from participants prior to treatment with BH~4~ (20 mg/kg/day). During the 4 weeks of screening for response to BH~4~ that followed, blood Phe was monitored weekly, and participants were instructed to maintain their usual diets. Phe levels recorded in the year preceding treatment were averaged to calculate baseline Phe, and Phe levels from the 4-week screening period were averaged to calculate percent reduction in blood Phe relative to baseline Phe. On this basis, individuals were classified as responders or non-responders to BH~4~ (Phe data are reported in [Table 3](#t0015){ref-type="table"}; secondary analyses were also run using lifetime mean Phe as the baseline metric against which screening Phe was compared, and results were consistent). Responders (*n* = 13; 8 males, 5 females) exhibited a reduction in Phe ≥ 30%, whereas non-responders (*n* = 16; 10 males, 6 females) failed to exhibit such change.

Age ranged from 9--35 years (M = 18.8, SD = 9.4) for responders and 8--33 years (M = 16.6, SD = 8.1) for non-responders. Pertaining to race/ethnicity, 8% of responders and 0% of non-responders identified as members of a minority group. There were no significant differences between responders and non-responders in age, gender, or race/ethnicity (*p* \> 0.05 in all instances).

Baseline cognitive and neuroimaging data from individuals with PKU were also compared with those of healthy controls (*n* = 12; 8 males, 4 females) recruited from the St. Louis community. Within the control group, age ranged from 7--33 years (M = 17.8, SD = 8.0), and 8% identified as members of a minority group. No control reported a history of major medical, psychiatric, or learning disorder, and there were no significant differences between individuals with PKU and controls in age, gender, or race/ethnicity (*p* \> 0.05 in all instances).

2.2. Procedures {#s0020}
---------------

Data included in this report are components of a longitudinal study exploring the effects of BH~4~ on biochemical, neural, and cognitive outcomes in individuals with early- and continuously-treated PKU. Approval for this study was obtained from institutional review boards at Washington University and University of Missouri, the sites at which all cognitive and neuroimaging data were collected. Participants and/or their guardians provided written informed consent prior to enrolling in the study, and the cognitive and neuroimaging components of the study were typically completed in a single session lasting 4 h. Previous manuscripts have reported data from the longitudinal dataset to explore differences in cognition and white matter integrity between PKU and control groups[1](#fn0005){ref-type="fn"}; however, pretreatment cognitive and neural differences between responders and non-responders have not been examined previously.

2.3. Phenylalanine {#s0025}
------------------

We evaluated 6 indices of Phe control. Of these indices, 3 were related to implementation of treatment with BH~4~ (baseline Phe, screening Phe, percent reduction in Phe) and 3 were related to Phe control over the lifetime prior to treatment with BH~4~ (mean Phe, SD Phe as an indicator of variability, index of dietary control \[IDC\]). Baseline and screening Phe were used to calculate percent reduction in Phe, thereby determining group status (i.e., responder, non-responder). Lifetime mean Phe and SD Phe were examined because they have been negatively associated with cognitive performance and white matter integrity [@bb0115], [@bb0120], [@bb0205] and are used with greatest ease in metabolic clinics. The IDC was examined to control for the fact that fewer Phe levels are typically obtained as individuals with PKU age; this index was computed as the mean of each individual\'s annual median Phe level, and thus provided a weighted average of lifetime Phe.

2.4. Intelligence {#s0030}
-----------------

IQ was estimated using a composite based on standard scores (standard score normative mean = 100, SD = 15) from the Matrix Reasoning and Vocabulary subtests of the Wechsler Abbreviated Scale of Intelligence (WASI; [@bb0210]). The two subtest scores were also examined separately because they provided estimates of performance and verbal IQ, respectively. Administration and scoring followed test manual instructions.

2.5. White matter integrity {#s0035}
---------------------------

Neuroimaging procedures are described in detail by Antenor-Dorsey et al. [@bb0015]. Briefly, scans were run on a Siemens TIM Trio 3.0 T imaging system (Erlangen, Germany). Diffusion tensor imaging (DTI) data reflecting microstructural white matter integrity were collected using an echo planar imaging (EPI) sequence along 25 non-collinear diffusion gradients \[TR = 12,437 (Washington University; WU) and 9900 (University of Missouri; UM), TE = 102 (WU and UM), flip angle = 90° (WU and UM), FOV = 864 × 864 (WU) and 768 × 768 (UM), voxel resolution = 2.0 × 2.0 × 2.0 (WU and UM)\]. Diffusion weighted images were registered to weighted structural images and then to an in-house atlas at Washington University. Parametric maps were subsequently generated for mean diffusivity (MD), the DTI component of interest in this study.

MD was compared across study groups using region of interest (ROI) and tract based spatial statistics (TBSS) analyses (FSL software, Oxford, UK; [@bb0195]). We did not control for age because groups were statistically equivalent on this metric, and previous analyses of DTI and cognition did not indicate significant interactions between age and group [@bb0015]. As in our previous studies [@bb0015], [@bb0115], [@bb0220], we focused on the following 10 white matter ROIs to provide a broad sampling across a range of brain regions: hippocampus, putamen, prefrontal cortex, optic radiation, posterior parietal-occipital, centrum semiovale, thalamus, and corpus callosum (genu, body, splenium). MD data from two non-responders were unavailable due to MRI contraindications and movement artifact, but this did not result in between-group demographic differences.

2.6. Statistical analyses {#s0040}
-------------------------

As a starting point, to minimize the number of group-wise (responder, non-responder, control) comparisons and thereby reduce Type I error rate, omnibus ANOVAs were conducted to examine the effect of group (responder, non-responder, control) on each intelligence and MD variable. When significant ANOVA results were obtained, one-tailed independent samples *t*-tests were conducted to examine the effect of group on each relevant intelligence and MD variable. Of particular interest were differences between responders and non-responders. *t*-tests were also used to explore differences in Phe indices between responders and non-responders.

To avoid masking novel results that may drive future research, we did not control for multiple comparisons and set our alpha level at 0.10. However, to maintain statistical rigor, we considered results significant only when *p*-values less than our alpha threshold were associated with medium or large effect sizes. To adjust for bias due to small sample size, Hedge\'s *g* and omega-squared (ω^2^) were used as measures of effect size for *t*-test and ANOVA comparisons, respectively. Consistent with conventions, *g* = 0.5 and ω^2^ = 0.06 designated medium effect sizes, and *g* = 0.8 and ω^2^ = 0.14 designated large effect sizes [@bb0065], [@bb0135]. A growing body of research supports our statistical approach, emphasizing the pitfalls of null hypothesis significant testing [@bb0070], [@bb0080], [@bb0085], [@bb0140] and the importance of effect sizes and confidence intervals [@bb0020], [@bb0075], [@bb0185].

3. Results {#s0045}
==========

3.1. Omnibus results {#s0050}
--------------------

As shown in [Table 1](#t0005){ref-type="table"}, omnibus ANOVA results revealed significant effects of group on IQ and Matrix Reasoning. With respect to MD, there were significant effects of group in 9 of 10 white matter ROIs: the hippocampus, putamen, prefrontal cortex, optic radiation, posterior parietal-occipital, centrum semiovale, and genu, body, and splenium of the corpus callosum. The effect of group on Vocabulary was not significant, nor was the effect of group on MD in the thalamus; as such, these variables were excluded from further analyses.Table 1Omnibus results comparing intelligence and MD among responders, non-responders, and controls.Table 1Statistical findingsFpω^2^Intelligence IQ4.690.020.15\* Vocabulary0.910.41\< 0.01 Matrix reasoning7.11\< 0.010.23\*ROI Hippocampus5.82\< 0.010.20\* Putamen5.63\< 0.010.19\* Prefrontal8.50\< 0.010.28\* Optic radiation12.43\< 0.010.37\* Parietal-occipital18.16\< 0.010.47\* Centrum semiovale10.73\< 0.010.33\* Thalamus1.190.32\< 0.01 Genu of CC15.81\< 0.010.43\* Body of CC9.01\< 0.010.29\* Splenium of the CC3.37\< 0.050.11\*[^1]

3.2. Control group comparisons {#s0055}
------------------------------

Although not the central focus of our study, to provide a normative context, we evaluated differences in intelligence and MD between controls and each of our PKU groups (see [Table 2](#t0010){ref-type="table"}). Regarding intelligence, IQ was significantly poorer for non-responders than controls. In addition, Matrix Reasoning performance was significantly poorer for both responders and non-responders than controls. In terms of white matter integrity results, MD was significantly lower for both responders and non-responders than controls in the putamen, prefrontal cortex, optic radiation, posterior parietal-occipital, centrum semiovale, and genu of the corpus callosum. MD was also significantly lower for non-responders than controls in the hippocampus and body and splenium of the corpus callosum. Thus, there were significant findings in 6 of 9 ROIs for responders and all 9 ROIs for non-responders, replicating findings from prior studies demonstrating poorer cognition and white matter integrity in individuals with PKU relative to controls (e.g., [@bb0015], [@bb0220]).Table 2Mean (SD) and statistical findings comparing controls vs. responders and controls vs. non-responders.Table 2Statistical findingsControl vs. RespondersControl vs. Non-respondersControlRespondersNon-responderstpHedge\'s *g*95% CItpHedge\'s *g*95% CIIntelligence IQ108.5 (10.6)104.2 (10.9)95.6 (12.5)1.010.160.39− 3.022.96\< 0.011.07\*5.48 Matrix reasoning113.4 (9.9)104.4 (11.4)97.6 (11.4)2.120.020.81\*1.123.92\< 0.011.42\*5.95ROI Hippocampus0.84 (0.02)0.87 (0.08)0.79 (0.06)1.240.880.48− 0.072.91\< 0.011.05\*0.02 Putamen0.71 (0.03)0.69 (0.04)0.66 (0.05)1.900.040.74\*0.003.47\< 0.011.26\*0.03 Prefrontal0.74 (0.05)0.72 (0.03)0.67 (0.05)1.380.090.53\*\>−0.013.64\< 0.011.38\*0.04 Optic radiation0.84 (0.04)0.79 (0.08)0.70 (0.08)1.720.050.67\*\>−0.015.59\< 0.012.01\*0.09 Parietal-occipital0.84 (0.05)0.75 (0.08)0.65 (.09)3.45\< 0.011.34\*0.046.18\< 0.012.26\*0.13 Centrum Semiovale0.73 (0.03)0.68 (0.07)0.61 (0.08)2.310.020.90\*0.015.3\< 0.011.89\*0.08 Genu of CC0.83 (0.09)0.71 (0.08)0.64 (0.09)3.59\< 0.011.39\*0.075.23\< 0.012.02\*0.13 Body of CC0.85 (0.06)0.82 (0.09)0.73 (0.06)0.990.170.38− 0.024.75\< 0.011.80\*0.07 Splenium of CC0.69 (0.05)0.71 (0.08)0.64 (0.07)0.850.800.33− 0.071.950.030.72\*0.01[^2]

3.3. Responder and non-responder comparisons {#s0060}
--------------------------------------------

### 3.3.1. Phenylalanine {#s0065}

Group differences in baseline Phe, screening Phe, percent reduction in Phe, lifetime mean Phe, lifetime SD Phe, and IDC were evaluated between responders and non-responders (see [Table 3](#t0015){ref-type="table"}). Baseline Phe was not significantly different between responders and non-responders, although in absolute terms baseline Phe was higher for non-responders. As expected given their central roles in determining group membership, significant differences in screening Phe and percent reduction in Phe indicated that blood Phe levels were reduced to a greater extent for responders than non-responders following implementation of treatment with BH~4~. A significant difference in SD Phe also emerged, indicating that variability in Phe over the lifetime was greater for non-responders than responders. In contrast, there were no significant differences in either mean Phe over the lifetime or IDC.Table 3Mean (SD) and statistical findings comparing indices of Phe control in responders and non-responders.Table 3Statistical findingsPhe (μmol/L)RespondersNon-responderstpHedge\'s *g*95% CIBaseline Mean (SD)588.3 (391.0)746.2 (353.4)1.130.140.41− 81.2 Range135.5--1598.3179.8--1271.3Screening Mean (SD)254.4 (181.9)789.6 (415.4)4.64\< 0.011.56\*336.7 Range69.5--741.6184.5--1541.8% Reduction Mean (SD)53.0 (16.1)− 6.7 (27.0)7.38\< 0.012.55\*45.9 Range32.2--87.4− 71.6--16.6Lifetime Mean Mean (SD)506.8 (262.9)566.3 (243.2)0.630.270.23− 102.7 Range250.3--1033.7179.8--1093.2Lifetime SD Mean (SD)213.1 (92.7)285.2 (145.4)1.620.060.56\*− 3.85 Range52.8--343.391.3--700.4IDC Mean (SD)506.2 (240.8)634.0 (316.9)1.230.110.46− 48.7 Range236.6--1000.2205.4--1435.8[^3]

### 3.3.2. Intelligence {#s0070}

Given significant ANOVA results, possible between-group differences in IQ and Matrix Reasoning were assessed in responders and non-responders (see [Table 4](#t0020){ref-type="table"}). In both comparisons, non-responders scored significantly poorer than responders. To situate these results within the context of the single identified group difference in Phe control, we examined correlations between intelligence and SD Phe in responder and non-responder groups; no results were significant.[2](#fn0010){ref-type="fn"}Table 4Mean (SD) and statistical findings comparing intelligence and MD in responders and non-responders.Table 4Statistical findingsRespondersNon-responderstpHedge\'s *g*95% CIIntelligence IQ104.2 (10.9)95.6 (12.5)1.980.030.71\*1.2 Matrix reasoning104.4 (11.4)97.6 (11.4)1.600.060.58\*− 0.4ROI Hippocampus0.87 (0.08)0.79 (0.06)2.83\< 0.011.07\*0.03 Putamen0.69 (0.04)0.66 (0.05)1.630.060.60\*\>−0.01 Prefrontal0.72 (0.03)0.67 (0.05)2.89\< 0.011.06\*0.02 Optic radiation0.79 (0.08)0.70 (0.08)2.92\< 0.011.09\*0.04 Parietal-occipital0.75 (0.08)0.65 (.09)2.87\< 0.011.06\*0.04 Centrum semiovale0.68 (0.07)0.61 (0.08)2.300.020.86\*0.02 Genu of CC0.71 (0.08)0.64 (0.09)2.110.020.78\*0.01 Body of CC0.82 (0.09)0.73 (0.06)2.83\< 0.011.07\*0.03 Splenium of CC0.71 (0.08)0.64 (0.07)2.290.020.86\*0.02[^4]

### 3.3.3. White matter integrity {#s0075}

Group differences in MD between responders and non-responders were similarly evaluated in ROIs for which omnibus results were significant (see [Table 4](#t0020){ref-type="table"}). Significant results emerged in all 9 ROIs (hippocampus, putamen, prefrontal cortex, optic radiation, posterior parietal-occipital, centrum semiovale, and genu, body and splenium of the corpus callosum), with lower MD for non-responders than responders. Irrespective of statistical significance, the chance odds that MD emerges numerically lower (and therefore farther from the value of controls) for non-responders than responders across all 9 ROIs is 0.0020.

Consistent with our ROI findings, TBSS analyses revealed widespread differences in MD (see [Fig. 1](#f0005){ref-type="fig"}A), with lower MD for non-responders than responders. We also examined white matter integrity in relation to SD Phe over the lifetime and found that higher SD Phe was associated with lower MD for non-responders (see [Fig. 1](#f0005){ref-type="fig"}B) but not responders.Fig. 1TBSS findings indicating (A) significantly lower MD in non-responders than responders and (B) a significant inverse correlation between MD and SD Phe in non-responders. Notes: green = TBSS skeleton; red = *p* \< 0.05, orange = *p* \< 0.03, and yellow = *p* \< 0.01.Fig. 1

4. Discussion {#s0080}
=============

Previous studies have identified biochemical and genotypic differences between BH~4~ responders and non-responders with PKU [@bb0110], [@bb0125], [@bb0130], [@bb0170]. However, very little research has sought to identify cognitive and neural differences between responders and non-responders. The present study aimed to address this gap in the literature by investigating baseline (i.e., prior to treatment with BH~4~) differences in indices of Phe control, intelligence, and white matter integrity between individuals with PKU who were subsequently identified as BH~4~ responders and non-responders.

To situate our results within the context of previous research, a majority of which investigated cognitive performance and white matter integrity in individuals with PKU relative to controls [@bb0015], [@bb0025], [@bb0060], analyses were conducted separately comparing intelligence and MD in responders and non-responders relative to controls. Consistent with prior research [@bb0010], [@bb0015], [@bb0165], [@bb0175], results indicated that individuals with PKU, regardless of response to BH~4~, exhibited poorer intelligence and white matter integrity than controls.

Turning to our central focus, we evaluated group differences between responders and non-responders. With respect to Phe, screening Phe and lifetime SD Phe were significantly higher for non-responders than responders, whereas percent reduction in Phe was significantly lower; there were no significant differences in baseline Phe, lifetime mean Phe, or IDC prior to treatment. Because screening Phe and percent reduction in Phe determined group status, differences between responders and non-responders were expected. The remaining indices of Phe control can be classified as quantifiers of variability in Phe (SD Phe) or Phe concentration (baseline Phe, mean Phe, IDC). As such, Phe variability but not concentration distinguished responders from non-responders, positioning SD Phe as a potential predictor of response to BH~4~.

With respect to intelligence, significant differences in IQ and Matrix Reasoning standard scores were observed, with poorer scores for non-responders than responders. A similar pattern emerged when neuroimaging data were examined, reflecting poorer white matter integrity for non-responders than responders prior to treatment with BH~4~. Specifically, MD was numerically lower for non-responders than responders in all 9 ROIs submitted to post-hoc analyses (the hippocampus, putamen, prefrontal cortex, optic radiation, posterior parietal-occipital, centrum semiovale, and genu, body, and splenium of the corpus callosum).

Corroborating ROI findings, TBSS analyses revealed that significantly poorer white matter integrity for non-responders than responders was widespread. Additionally, TBSS analyses revealed significant inverse correlations between MD and SD Phe in non-responders but not responders, again pointing to the possible predictive utility of SD Phe.

Collectively, results from our study indicate that BH~4~ non-responders differ from responders on the basis of variability in Phe over the lifetime and a number of variables reflecting intelligence and white matter integrity. It is possible that more fine-grained estimates of effect size and/or additional significant differences in Phe, intelligence, and white matter integrity might have been identified in a larger sample. Because PKU is a rare disorder affecting \< 0.01% of the United States population [@bb0035], recruitment of large samples is inherently difficult, but through collaborative efforts future studies might address our sample size limitation. In turn, in conjunction with genotypic data, Phe, intelligence, and white matter integrity data might be used to develop a powerful predictive model of response to BH~4~ in a larger sample of individuals with PKU.

Conflict of interest {#s0085}
====================

This study was funded by an Investigator Sponsored Trial award from BioMarin Pharmaceutical Inc. Drs. White, Grange, and Christ have served as consultants and received research funding from BioMarin Pharmaceutical Inc. The content of the article has not been influenced by these relationships.

This research was supported by an Investigator Sponsored Trial award from BioMarin Pharmaceutical Inc. (BMRN/40716) and the Intellectual and Developmental Disabilities Research Center at Washington University with funding from the National Institute of Child Health and Human Development (U54HD087011). The authors wish to thank those who participated in our study for their contributions. We also thank Suzin Blankenship, Elizabeth Toolan, and Laurie Sprietsma for their contributions to study management, as well as the physicians, faculty, and staff of Washington University, University of Missouri, University of Florida, St. Louis University, New York Medical College, and University of Nebraska who generously contributed through recruitment and phenylalanine monitoring.

Sample size may differ slightly across studies due to variations in exclusion criteria. The present study excluded participants if response to BH~4~ was unknown, IQ data were unavailable, or age was \< 7 years at baseline.

Baseline Phe, mean Phe, and IDC were not included in correlational analyses because they did not differ significantly between responders and non-responders; screening Phe and percent reduction in Phe were not included because they determined group membership.

[^1]: Note: asterisks denote statistically significant results; F = variance between groups/variance within groups; ω^2^ = omega-squared; degrees of freedom = (2, 38) for intelligence variables and (2, 36) for ROIs.

[^2]: Notes: asterisks indicate statistically significant between-group difference; upper bound of all one-tailed confidence intervals is infinity.

[^3]: Notes: asterisks indicate statistically significant between-group difference; upper bound of all one-tailed confidence intervals is infinity.

[^4]: Notes: asterisks indicate statistically significant between-group difference; upper bound of all one-tailed confidence intervals is infinity.
